iBET is the most recent member of the Animal Cell Technology Industrial Platform (ACTIP). iBET application to join ACTIP as a non-profit organization was unanimously approved during the most recent ACTIP plenary meeting, hosted by Merck Life Science in Germany on the 21st and 22nd of November.
ACTIP plenary meeting featured high-level presentations on the topics “Technologies for cell and gene therapy manufacturing” and “Innovation in Biopharma”, covered by invited speakers from academia and ACTIP members. Manuel Carrondo, Vice-President of iBET, presented a communication entitled “Translational requirements for bioprocessing of cell and gene therapy products”.
ACTIP is an informal forum of European companies with significant activities in animal cell technology, aiming to stay on top of the cutting-edge research developments in this exciting field. Topics discussed on ACTIP include the production of biopharmaceuticals, monoclonal antibodies, vaccines, gene therapy vectors and safety testing.
Being part of ACTIP is a major opportunity to leverage iBET’s competences in Animal Cell Technology to a superior level.
